The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 914: 6. Changes made in revising the Model List: 6.1 Applications for additions: 6.1.7 Miconazole nitrate buccal tablets

The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 914
(2003; 132 pages)

Table of Contents

WHO Expert Committee on the Selection and Use of Essential Medicines
1. Introduction
2. Open session
3. The new procedures for updating and disseminating the Model List
	3.1 Background
	3.2 Key features of the new procedures
	3.3 Review of the new procedures
		3.3.1 Applications for additions
		3.3.2 Applications for deletions
		3.3.3 Selection criteria
	3.4 The WHO model formulary
	3.5 The WHO Essential Medicines Library
4. Other outstanding technical issues
	4.1 Change of name of the Expert Committee
	4.2 Description of essential medicines
	4.3 Role of treatment costs in relation to the Model List
	4.4 Inclusion of additional items in the Model List
5. Format and presentation of the 12th Model List
	5.1 Section headings
	5.2 The core and complementary lists
	5.3 The “square box” symbol
6. Changes made in revising the Model List
	6.1 Applications for additions
		6.1.1 Antiretroviral medicines
		6.1.2 Artemether + lumefantrine (fixed-dose combination)
		6.1.3 α/β-Arteether
		6.1.4 Artemotil (β-arteether)
		6.1.5 Amodiaquine
		6.1.6 Insecticide-treated bednets
		6.1.7 Miconazole nitrate buccal tablets
	6.2 Applications for deletions
	6.3 Other changes
		6.3.1 Meglumine antimoniate
		6.3.2 Antineoplastic and immunosuppressive medicines
		6.3.3 Reserve list medicines
7. Future reviews of sections of the Model List
	7.1 Update on the review of medicines for the treatment of hypertension
	7.2 Review of the core and complementary lists
	7.3 Review of the use of the “square box” symbol
	7.4 Review of injectable medicines
	7.5 Priorities for further systematic reviews
8. Recommendations
	8.1 Procedures for updating and disseminating the Model List of Essential Medicines¹
	8.2 Description of essential medicines
	8.3 Presentation of the 12th Model List
	8.4 Additions and changes to the Model List
	8.5 Deferred applications
	8.6 Rejected applications
	8.7 Priorities for future reviews of sections of the Model List
	8.8 Change of name of the Expert Committee
	8.9 Other recommendations
Acknowledgements
References
Annex 1 The 12th WHO Model List of Essential Medicines
Annex 2 Additional notes on the medicines recommended for inclusion in the 12th WHO Model List of Essential Medicines
Annex 3 The Anatomical Therapeutic Chemical (ATC) classification system¹
Alphabetical list of essential medicinces (with ATC classification codes)

6.1.7 Miconazole nitrate buccal tablets

The Committee reviewed the application for the inclusion of miconazole nitrate buccal tablets¹. The Committee recognized that miconazole ointment or cream was already on the Model List, as an antifungal medicine (for topical use). The absence of comparative data for miconazole nitrate buccal tablets and nystatin lozenges was of concern to the Committee. It concluded that, as insufficient evidence was presented as to its comparative advantage in efficacy and safety, miconazole nitrate buccal tablets should not be added to the Model List.

¹ The full application is available from the WHO Essential Medicines Library via the Internet at http://mednet3.who.int/mf/.